Expert Financial Analysis and Reporting

One Approach for Investing in Emerging Biotechnology Stocks I write on biotechnology and pharmaceutical companies of all sizes, but I have spent much of the last year focusing on small biotechnology companies ranging in size from as low as $50 million in market capialization.to about $400 million. There is much less analyst and investor attention […]

Intermezzo was launched by Transcept’s marketing partner Purdue in April 2012. I believed then and now that it is a highly effective product and fills a unique niche for middle of the night insomnia. Sales in 2012 were disappointing, but Purdue stepped up in major way to relaunch the product late last year with a […]

Intermezzo was launched by Transcept’s marketing partner Purdue in April 2012. I believed then and now that it is a highly effective product and fills a unique niche for middle of the night insomnia. Sales in 2012 were disappointing, but Purdue stepped up in major way to relaunch the product late last year with a […]

Introduction Over the last year, I have written seven articles on Transcept (TSPT) and if you would like to have a more in-depth view of my thinking on the product. I would urge you to review those articles either on Seeking Alpha or my website SmithOnStocks.com. This report focuses primarily on the progress of the […]

Investment Opinion The launch of Intermezzo has been disappointing to investors thus far. Now, Transcept’s (TSPT) marketing partner, Purdue Pharmaceuticals, is beginning a new phase of the launch with a direct to consumer advertising campaign and is employing for the first time its 500+ pain specialist sales force, the crown jewel of the company. The […]

Investment Overview The launch of Intermezzo began on April 4, 2012 and so far, it has been disappointing for investors. Purdue and Transcept (TSPT) have just announced a major new stage in its commercialization strategy that I believe may be the tipping point for a significant upward inflection in sales and I believe that this […]

Investment Opinion and Overview Now is the moment of truth for Transcept (TSPT) as the launch of Intermezzo has begun. I recommended Transcept in a report published on January 24, 2012 and I continue to recommend the stock. I would suggest that investors who need a refresher or are not familiar with the Transcept story […]

Investment View I believe that Transcept’s (TSPT) Intermezzo is an important new drug for insomnia and will be a commercial success. I am anticipating that Transcept’s marketing partner Purdue Pharmaceuticals will launch the product in mid-2012. There was a time when new product approvals and launches produced investor exuberance. Now they seem to be met […]

Investment View I believe that Transcept’s (TSPT) Intermezzo is an important new drug for insomnia and will be a commercial success. I am anticipating that Transcept’s marketing partner Purdue Pharmaceuticals will launch the product in mid-2012. There was a time when new product approvals and launches produced investor exuberance. Now they seem to be met […]

Resubmission of Intermezzo NDA Transcept Pharmaceuticals in a press release today (September 15) said that it plans to resubmit its NDA on Intermezzo following a meeting with the FDA. The key parts of the resubmission are: Transcept proposes to reduce the recommended Intermezzo dose for women from 3.5 mg to 1.75 mg, and to keep […]